Pediatric-onset multiple sclerosis (POMS), once thought to be rare, is now being diagnosed in increasing numbers in children. Despite improvements to diagnostic criteria, the diagnosis and management of POMS remains challenging. The aim of this study is to retrospectively describe a growing POMS patient population seen at a single center over a 13 year period. Epidemiologic, clinical, neuroimaging, laboratory features and therapeutic management and outcome data were collected and analyzed. These data support associations between MS and environmental triggers such as obesity and vitamin D deficiency. Presenting symptoms, magnetic resonance imaging and laboratory findings were consistent with the existing literature; however, the prevalence of cortical lesions and abnormal saccadic pursuit is higher than other reports. Data also demonstrate a shift in practice from first-to second-line therapies over the observed period.
Multiple sclerosis (MS) is classically viewed as an autoimmune disease of adulthood. However, it is being increasingly diagnosed in the pediatric population. Pediatric-onset multiple sclerosis (POMS) became a recognized disease entity only 50 years ago, despite early descriptions by Charcot and Marie extending back to the mid-1800s. 1 Since Charcot's original description and numerous reported case series thereafter, there has been substantial progress in understanding the disease manifestation, yet the pathogenesis and optimal management regimens remain elusive.
There are approximately 400 000 individuals with MS in the United States, of which 2-5% experience their first attack before 16 years of age. [2] [3] [4] [5] [6] In juveniles, the prevalence of disease increases with age throughout adolescence. Prepubertal boys and girls appear to be equally affected, whereas there is a female predominance in the postpubertal years that more closely reflects the gender discrepancy in adults. Environmental factors have been highlighted as potential risk factors to developing MS, including childhood obesity, Epstein-Barr virus infection, and vitamin D deficiency. Recent interest in the association between childhood obesity and the development of adult MS [7] [8] [9] has led to similar studies in POMS that noted higher rates of obesity in the POMS population compared to controls. 10 MS is a clinical diagnosis in both adults and children, the latter guided by the 2012 International Pediatric MS Study Group criteria. 11 In young children, MS often presents with multifocal symptoms, but as they enter adolescence, the presenting symptoms are increasingly monofocal, resembling that of the adult disease form. 12 The clinical course of POMS is relapsing-remitting in approximately 95% of patients. 13 Children tend to have more frequent and severe relapses, and better recovery as compared to adults with MS.
14 Disease activity can be monitored by the appearance of new or worsening symptoms and by appearance of new lesions on magnetic resonance imaging (MRI) that may not be clinically symptomatic. The most common manifestations in children include sensory (15-30%), motor (30%), and brainstem dysfunction (25-41%). 13 MS is an unrelenting, slowly progressive disease. Thus, the goal of treatment is to prevent disease progression and delay the time to the secondary-progressive stage, which is associated with accumulation of disability. Currently, POMS is managed with a number of immunotherapies that have been approved for use in adults. To date, there are no completed clinical trials investigating disease-modifying therapies (DMTs) in POMS, but 3 trials are currently ongoing. 15 However, 2 treatments approved for use in adults, beta-interferon (eg, Avonex) and glatiramer acetate (Copaxone), are widely used in pediatrics and are the currently accepted standard of care. 4 30% of patients fail first-line medication and aggressive management is indicated to lessen long-term disability. 15 The increasing number of children diagnosed with MS has highlighted a need for pediatric-specific centers to manage these patients. Furthermore, the young age at which they experience relapses is during critical social and cognitive developmental periods of their lives. 16 Here the authors describe the clinical characteristics of a POMS population upon initial presentation to a single institution, and outcomes of treatment as they progress into adulthood. The cohort includes 1 of the youngest reported POMS patients, shows a high prevalence of abnormal eye movements, and demonstrates a change in practice from first to second-line therapy use over time.
Methods
In this retrospective study, the authors evaluated all patients who presented to a single academic institution, received a diagnosis of multiple sclerosis between 2002 and 2015, with an initial attack before 18 years of age. Patients who presented to another institution for treatment of an initial attack and were subsequently referred to the authors' institution were also included. As the diagnostic recommendations for POMS were revised multiple times during the study period, patients were diagnosed according to the most recent recommended criteria. Patients who presented between 2002 and 2005 were diagnosed using the 2001 McDonald criteria, and those who presented between 2005 and 2010 were diagnosed using the 2005 revised McDonald criteria. The current diagnostic guidelines, the 2010 revision of the McDonald criteria, were used to diagnose patients who presented later than 2010. Only patients whose diagnoses were maintained throughout follow-up were included in the study. Sixty-four patients met the original criteria, and 4 patients were excluded due to continued uncertainty of the MS diagnosis or subsequent consideration of other diagnoses. Study data were collected and managed using REDCap electronic data capture tools. 17 The following data were collected based on availability of records:
Demographics
Age at presentation, gender, race and ethnicity, and anthropometrics were collected from the electronic medical record.
Clinical Presentation
The authors gathered information on presenting symptoms, family history of MS, clinical findings on initial presentation, brain and spine MRI, blood, and cerebrospinal fluid studies. Presenting symptoms were those reported in the history of present illness as reasons for seeking care at the authors' institution. If pertinent, this included symptoms that preceded initial work-up at outside institutions. Clinical findings were recorded in the medical record during the first visit to the authors' institution. Presenting symptoms were gathered from patient and parent/guardian report and clinical findings were recorded from the neurological examination during the initial visit. Both symptoms and clinical findings were broadly classified as sensory (eg, numbness, tingling, light touch), motor (eg, weakness, reflexes, tone), visual (eg, blurred vision, abnormal visual acuity, visual field defects, optic neuritis, saccadic eye movements), cerebellar (eg, balance, ataxia), sphincter disturbance, and other symptoms as detailed in the results. All pediatric MS patients were evaluated by 1 of 2 dedicated pediatric MS specialists. Investigational information collected included brain and spine MRI studies, blood, and cerebrospinal fluid studies. Imaging data was gathered through a combination of neuroradiology written report, as well as MS specialist neuroradiologist and MS physician review.
Treatment
Treatment for initial attack, initial DMT, and the DMT at last consultation were recorded. Data on treatment were collected from initial patient presentation until last consultation, including patients who transitioned to the adult MS center. For patients who were started on DMT prior to referral to the authors' clinic, this DMT was used as their first DMT. Patients who received DMT and who had at least 1 follow-up were included in treatment analyses.
Outcomes
The number of relapses was found in patient charts and an annual relapse rate was calculated. The authors documented the relapse information for patients over the course of their individual followup period (months) after beginning DMT. Relapses were defined as the presence of new onset or worsening neurologic symptoms that last at least 24 hours, and occurring greater than 30 days following a previous clinical event.
For analyses of DMT utilization, only patients who started and remained on DMT at last consultation were included. For analyses of relapse frequency, all patients who returned for follow-up were included. To ensure accuracy of relapse recall of referred patients, only patients who were seen within 12 months of initial symptom onset were considered. Annual relapse rate is reported in person-years.
Statistical Analysis
The authors described the study population using counts and percentages for categorical variables, and means with standard deviation for continuous variables. Analyses were performed using JMP software, version 11 (SAS Institute Inc, Cary, NC, 2013).
Results

Patient Demographics
The authors identified 60 patients who fit the criteria for this study. Their demographic information is shown in Table 1 . The mean age at presentation was 15.7 years (+2.9), with the age range of the cohort being between 2.5 and 19 years old. For this group, the mean BMI ¼ 25.1 kg/m 2 (+5.7). Of the patients for whom BMI measurements were recorded (n ¼ 39), approximately half (49%) qualified for either being overweight (n ¼ 7) or obese (n ¼ 12) based on CDC growth charts, and 6 patients had a BMI > 30 kg/m 2 . Nearly 70% of the cohort was female (n ¼ 41). When stratified by age, females were predominant in both the under and over 12-year-old groups, 67% and 80%, respectively. The patient demographic was primarily Caucasian (78%). Approximately 32% of patients identified at least 1 relative with MS.
Presenting Symptoms
The most commonly reported symptoms were sensory by 78% of patients, followed by motor symptoms in 50%, and visual symptoms in 48%. Cerebellar and sphincter dysfunction was reported by 35% and 7% of patients, respectively. Seven patients (12%) reported experiencing Lhermitte's sign. The majority of patients (70%) also reported other frequent symptoms including headache, dizziness, nausea, fatigue, and memory or concentration disturbance.
Clinical Findings
On clinical examination, the most prevalent finding was visual dysfunction in 50% of patients. Motor dysfunction and cerebellar dysfunction were present in 43% and 38%, respectively. Sensory dysfunction was noted in 25% (n ¼ 25) of patients. 53% of patients had cranial nerve dysfunction, most notably CN II, III, IV, or VI. The most common findings were decreased visual acuity (n ¼ 11) and saccadic pursuit abnormalities (n ¼ 21). Five patients had an afferent pupillary defect, but no patients had an internuclear ophthalmoplegia. were identified as abnormal (normal < 0.62). Of 28 patients evaluated for the presence of oligoclonal bands (OCB), 72% tested positive (Table 2) .
Imaging
Brain Imaging. MRI reports prior to any initiation of diseasemodifying agents were included in the analysis. A vast majority of children (85%) had periventricular white matter lesions. Other highly reported sites included corpus callosum (55%), subcortical (51%), brainstem (46%), and cerebellum (28%). A smaller percentage of patients' MRIs showed lesions in the cortical regions (15%), deep white matter (WM) (12%), and internal capsule (12%) ( Table 3 ).
Spine Imaging. Of children, 40% presented with cervical spine lesions. Thoracic spine lesions were noted in 15% of patients (Table 3) . Imaging of the lumbar spine is not standard of care at the authors' institution, though of the patients who had lumbar imaging at outside hospitals, no lesions were identified.
Treatment Acute Management
Of the first time patients who sought medical attention for MS symptoms, a quarter (26%) of the patients did not receive any Abbreviations: n, number of patients; WM, white matter; GM, gray matter. acute treatment, but went on to maintenance DMT. The majority (69%) of patients were started on IV methylprednisolone followed by a 2-week oral steroid taper. Few patients (n ¼ 5) who were initially seen by an outside institution were started simultaneously on steroids for acute management and longterm maintenance therapy with interferons.
Disease-Modifying Therapy. There are several ongoing clinical trials evaluating the use of second-line DMT in POMS. 15 Currently, interferons and glatiramer acetate are accepted as the mainstay of treatment for this population. Beta interferons were the first DMT for 83% of patients (n ¼ 48) (Table 4) . Avonex (n ¼ 42) is the interferon of choice for the authors' clinic; however, 5 patients were taking Rebif and 1 patient was taking Betaseron, which had been prescribed at outside hospitals. Fewer patients were initially started on glatiramer acetate (12%, n ¼ 7), azathioprine (3%, n ¼ 2; both from outside hospitals) and natalizumab (2%, n ¼ 1). Forty-two patients met the requirements for analysis at last consultation, which included current DMT and relapse outcomes (Table 4) . Of the patients who started DMT with beta interferon, 45% remained on beta interferon at their last follow-up. In contrast, while dimethyl fumarate was never used as a first DMT, over a quarter of patients receiving DMT were using dimethyl fumarate (26%) at their last follow-up. Similarly, patients were being prescribed fingolimod (n ¼ 4) and natalizumab (n ¼ 3) more frequently as their disease progressed, and following transition to the adult care clinic. At last consultation, 4 patients who had initially started DMT, had discontinued DMT for various reasons, and were not included in the analysis.
Relapse
Relapse data was gathered on patients who were seen at the authors' institution within 12 months of initial symptom onset (n ¼ 42) to ensure a more accurate history. Follow-up duration ranged from 2 to 151 months, with an average length of followup of 68 months (+38.3). The annualized relapse rate (n ¼ 42) was 0.54 relapses per person-years follow-up (129 relapses; 2874 months of follow-up) for the whole cohort. Patients who were being treated with DMT at last consultation had an annualized relapse rate of 0.53 and patients who were not on DMT had 0.61 relapses per person-years. Duration of time between first and second relapse was 14.9 months (+17.0).
Discussion
This study describes demographic and clinical features of POMS patients who presented to a single institution over a 13 year period, in addition to reporting the variety of immunotherapies utilized at a single center. In concordance with previous studies, there was a 2:1 female predominance, which was more pronounced in patients over 12 years of age.
Obesity
The authors found 49% of the cohort to be overweight or obese, and in support of the association between childhood obesity and POMS. [6] [7] [8] Further analyses showed that overweight or obese children had a higher mean annualized relapse rate compared to children who fell into the healthy BMI category. This study was not powered for such analyses and neither comparison reached significance. However, this mild trend in a small population underscores recent research in the association between obesity and MS. 7, [18] [19] [20] Obesity at early adulthood 9, 21 was shown to increase risk of adult-onset MS at least 2-fold, whereas a 1-unit increase in BMI z-score of children 7 to 13-years-old was associated with a 20% increase in risk. 18 Interestingly, 1 study demonstrated that this risk was significant only for females. 7 To the authors' knowledge, only 1 study assessed childhood obesity as a risk factor for childhood-onset multiple sclerosis and acquired demyelinating disease, and demonstrated a significant association between obesity and MS for girls in the 12 to 18-year-old range. 19 Larger prospective studies would help shed light on this association, particularly as it relates to the development of POMS. It may be of increasing importance as pediatric obesity is currently at the forefront of modern childhood health issues.
Vitamin D
A large proportion of the patients were vitamin D deficient prior to starting DMT. The role of vitamin D deficiency in MS originates from studies that highlight latitudinal gradient in MS prevalence. 22 It has since become 1 of the major environmental associations with MS. However, the role of vitamin D in disease pathogenesis and progression of disease has been investigated without clear consensus. Pilot studies evaluating effect of vitamin D supplementation in adults could not confirm a positive impact on disease course. 23, 24 One prospective study found vitamin D status inversely correlated with relapse rate in children, such that a 10 ng/ml increase in 25(OH) vitamin D was associated with a 34% decrease in relapse rate. 25 In addition, obesity may play a role in establishing vitamin deficiency, as vitamin D is fat soluble and can be sequestered in adipose tissue. 26 This has been supported by recent work that showed race and obesity were independent predictors of vitamin D status. 27 
Genetic Risk Factors
Genetic risk factors also may play a role in development of MS. The authors found a high proportion (32%) of the patients to have a family history of MS (Table 1) , whereas other studies have shown family history of MS to be reported by 6%-21% of POMS patients. 3 The strongest associated genes are the human leukocyte antigen (HLA) alleles. HLA-DRB1*15 is believed to be a susceptibility allele and HLA-A*02 may be protective. 8 The interaction between obesity, vitamin D status, previous viral infection, and HLA risk genes has been investigated. 8 
Clinical Findings
The most common symptoms at presentation in the study were sensory in nature, followed by motor and visual symptoms. While sensory symptoms have been reported among the most prevalent in some reports, 13 it has been among the least in other studies. 31 Of those studies that report sensory symptoms as a primary cause for seeking medical care, the frequency is typically reported to be less than 50%, whereas 70% of patients in the study reported sensory symptoms prior to medical care. In contrast, sensory findings were identified less frequently on clinical examination in the patients. This may reflect a longer duration of time between initial symptom onset and the clinic appointment, though the authors did not investigate this further. The most common clinical finding on examination was oculomotor findings, in contradistinction to other studies that report motor dysfunction as the most frequent clinical finding. 12, 31 Abnormal saccadic eye movements was a prominent finding that is not often reported in the POMS literature. In adult patients the prevalence of saccadic eye movement abnormality is 80-90%. 32 In correlation with MRI findings, further analysis showed that 14 of the 21 patients who had abnormal saccadic eye movements also had brainstem lesions.
Neurocognitive Dysfunction
Despite lack of official assessment, patients and caregivers identified cognitive and memory dysfunction as prominent presenting symptoms. At the authors' institution, neuropsychometric testing was not performed routinely for earlier portions of the study period. When this study began, the authors' understanding of cognitive impairment in POMS was still in its infancy. Since then there has been an increasing number of studies on cognitive function in POMS, and these have shown impairment in a number of cognitive modalities. [33] [34] [35] Future studies should focus on more rigorous evaluation of these parameters to determine whether there is an association between early presentations of neuropsychologic dysfunction and relapse trajectory.
The onset of POMS poses a threat to normal neural development in children, which is unique from the damage sustained in the adult brain. However, whether cognitive deficits in POMS are due to parenchymal atrophy or impeded brain development remains unknown. Deficits incurred in POMS have been shown to be progressive, as demonstrated by few longitudinal studies over a 2-to 5-year period. 36, 37 Fatigue/Psychological Issues Fatigue and psychological issues such as depression are often noted in MS. Of the cohort, 15% reported fatigue and 2 patients noted changes in mood. In the multiple sclerosis literature, fatigue is reported in between 20-50% of children, whereas it is also reported in up to 20% of the healthy young population. 38 The frequency of fatigue in the study does not fall within this range, and may reflect a lack of routine formal evaluation at the authors' institution.
Treatment
Beta interferons (eg, Avonex, Rebif) and glatiramer acetate (Copaxone) are considered first-line therapies in the management of POMS. Both treatments are supported for use in POMS by the International Pediatric MS Study Group, despite lack of rigorous clinical trial testing in this population. 4 Years of offlabel use suggests that these therapies are relatively safe. 39 As anticipated, this study identified beta interferon as the most frequent choice of first DMT, followed by glatiramer acetate. For many of the patients, interferon therapy continued to be effective over the follow-up period; however, there were also patients who were resistant to interferon therapy, and whose disease progressed rapidly. Through descriptive analyses of the authors' patient population, the authors identified that a significant number of patients move to stronger medications at early ages. Such patients require second-line treatments that are currently only approved for use in adult MS.
There has been reported success with off-label use of a few second-line therapies in POMS. [40] [41] [42] Three second-line DMTs were reported in the study: fingolimod, dimethyl fumarate, and natalizumab. These DMTs are generally more effective, prominently reducing relapse rates and/or MRI lesion load without commonly encountered severe adverse risks. [43] [44] [45] While these DMTs are not approved for POMS, the authors report that 7 patients who were receiving a second-line DMT at the last consultation initially began second-line DMT before 21 years of age, without significant side effects.
There are currently ongoing clinical trials for fingolimod (NCT01892722), natalizumab (NCT02137109), and dimethyl fumarate (NCT02428218) in POMS, which will be critical for a more controlled assessment of the efficacy, adverse effects, and dosing for children. 15 These clinical trials will constitute the first rigorous assessments of DMTs in POMS. As therapies are validated for POMS, clinicians must weigh clinical symptoms and early neuropsychological decline against the initiation of potent and life-long immunomodulatory therapies, some of which have serious potential complications.
Outcomes/Relapse
In contrast to previous findings, the authors found a longer duration between first and second attack at an average of 14 months. Overall, the patients had a mean annualized relapse rate of 0.54 relapses per person-years. In POMS, the relapse rate is greater than that in adult onset MS, 1.13 compared to 0.40 relapses per person-years. 46 A 2011 review by Banwell et al demonstrated that mean annualized relapse rates during beta interferon treatment of POMS ranged from 0.21 to 1.63, demonstrating the variability of patient response to treatment. 39 Natalizumab has been reported to improve relapse frequency in POMS, with annual relapse rates decreasing from 2.4 prior to natalizumab treatment to 0.1 at the end of the study. 41 In the study patients were not bound to a specific therapy and were able to change treatments as necessary for their disease. However, annual relapse rates for patients who remained on beta-interferon was 0.31 relapses per person-years, within range reported in the Banwell et al review. 39 When assessing only patients who were last on second-line DMT, the annual relapse rate was 0.63 relapses per person-years. This may be a reflection of more active disease, as these are the patients likely to be placed on higher efficacy medication.
Strengths/Limitations
The small sample size clearly limits the statistical analyses that can be performed. Any nondescriptive analyses lacked power to make any comparison statements with confidence. This study was also limited in the outcomes analyses that could be conducted. The authors accounted for differences in follow-up time by measuring person-years of follow-up. In the authors' assessment of treatment and relapse outcomes, the authors report initial DMT and most recent DMT. However, the authors do not address any therapeutic interventions that may have occurred in the interim or reasons for switching from 1 DMT to another. This may provide important information regarding patient preferences, which, when aligned with their therapy, can improve compliance.
Conclusion/Future Directions
POMS is a complex disease which causes multiple symptoms and signs, and poses unique challenges in management. This retrospective study assessed presentation, investigation, and treatment of POMS patients at a single institution. Interesting findings from the study include the presence of abnormal saccadic pursuit which is rarely discussed in the POMS literature, and also an increased utilization rate of second-line DMT in patients with relapsing disease. Based on the authors' experience and the current literature on POMS, the authors would recommend universal neuropsychometric evaluation and further evaluation of second-line therapies in treatment-refractory patients.
New therapies hold promise for greater relapse prevention and patient adherence to therapy, given the increasing potency and convenience of oral administration. [43] [44] [45] As outlined by the International Pediatric MS Study Group, future novel therapies should be considered for evaluation in the youth following successful completed studies in the adult population.
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Ongoing and future clinical trials will provide clinicians with confidence in new options to treat MS in the young. These clinical trials evaluating the use of adult onset MS secondline DMTs in POMS mark progress in expanding treatment options for children. Follow-up from these studies will be necessary to assess long-term side effects, which will contribute to the selection of DMT. Even then, clinicians must weigh the risks and benefits of effective therapy against the well-being of the patient and further progression of disease.
MS is a complicated neurologic disease which can cause early impairment and need for assistance in multiple aspects of life, of which many are currently unmet. 47 The neuropsychologic impact on POMS patients is clearly evident from recent publications on this topic. Identification of a specific cognitive pattern for MS may help identify patients early and connect them with appropriate aids. Furthermore, delineating the temporality of neuropsychological decline will be important, as this will further understanding of disease progression. Patients should be properly assessed for potential physical, emotional, and cognitive disabilities, the latter by neuropsychometric evaluation or future imaging studies. For children, counseling and planning for necessary accommodations may give them the best opportunity for academic success and quality of life. Highlighting future education, psychological and social support services will ensure doctors have options that are relevant and useful to patients with MS.
